Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HUC-MSCs for Aging Frailty
NCT04314011Phase 2Completed
- Sponsor
- Shanghai East Hospital
- Start
- Jun 2020
- Primary completion
- Dec 2021
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of human umbilical cord mesenchymal stem cells in frailty syndrome (2 arms), sponsored by Shanghai East Hospital. Primary endpoint: Safety of HUC-MSCs infusion at 1 month. Started Jun 2020; status: completed.
02
Drugs
human umbilical cord mesenchymal stem cells
03
Conditions
frailty syndrome
Beyond the preview
Go deeper on NCT04314011.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04314011.